AION Labs Innovation Labs Ltd.

aionlabs.com

Venture Studio

Tech Verticals Preferences

Artificial Intelligence, BioConvergence, BioPharma, Biotechnology, Digital Health, Healthtech, Machine Learning, MedTech, Pharmaceuticals

General Data

Established	2020
Current Active Portfolio Companies:	7
Reg. Number:	abCDe

DESCRIPTION

AION Labs is a first-of-its-kind alliance of AstraZeneca, Merck, Pfizer, Teva, the Israel Biotech Fund, Amiti Ventures and Amazon Web Services (AWS) that have come together with one clear mission: to create and adopt groundbreaking new AI technologies that will transform the process of drug discovery and development in order to contribute to the health and well-being of all people world-wide.

Located within the Israeli biotech hotspot in Rehovot adjacent to Weizmann Institute for Sciences, AION Labs is a unique venture hub where brilliant innovators convene from around the world to solve the biggest R&D challenges guided by years of accumulated know-how, data and experience in pharma. The lab leverages its partners’ wealth of knowledge and a new multidisciplinary mindset with the ingenuity, agility and innovative power of Israel’s start-up ecosystem, to develop strong companies with clear long-term strategies, that will pave the way to the future of healthcare. AION Labs cultivates innovation from within; its unique venture creation process bridges the gap between outstanding academic research in the field of AI and the biggest R&D needs in the discovery and development of new medicines for the benefit of patients.

PARTNERS & SPONSORS

Company Name	Type	Partner/Sponsor
BioMed X Institute	Other	Partner
Israel Innovation Authority	Government Agency	Partner

REMARKS

Date	Remark
01/03/2023	AION Labs invested in DenovAI, a foreign founded, Israeli registered and based company.
29/12/2020	AION Labs has received a 5 year license from the Israel Innovation Authority to manage an open innovation center.

CONTACT INFO

Expand / Collapse All

Main Address: Rehovot, Israel

Address	4 Prof. Hillel Vehanan Oppenheimer St. Rehovot Science Park
City	Rehovot
Country	Israel
Zip	7670105

Contact Person	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Mr. Mati Gill	CEO
Dr. Yair Benita	CTO	Cytoreason (Head of Scientific Operations)
Ms. Einav Daniel	Finance Director
Ms. Sharon Ein-Gal	Alliance Principal

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Board Member	Managing Partner, Israel Biotech Fund
abC Defghij	Board Member	Partner, Israel Biotech Fund

	FINANCIAL ROUNDS

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

Investment in Fund

Dec. 01, 2020

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Venture Capital Fund	abCDe
abC Defghij	Venture Capital Management Company	abCDe
abC Defghij	High-Tech Company	abCDe
abC Defghij	Other	abCDe
abC Defghij	Other	abCDe
abC Defghij	High-Tech Company	abCDe
abC Defghij	High-Tech Company	abCDe
abC Defghij	High-Tech Company	abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Jun. 01, 2024

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Government Agency	abCDe

Investment Data

Preferences

Maximum investments	$2m
Type of Financing	Equity
Stage Preferences	Seed

SECTOR SEGMENTATION (By Number Of Companies)

Biomed

57%

Digital Health

29%

Medical Devices

14%

	PORTFOLIO COMPANIES

Current Portfolio Companies (7)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Cassidy Bio

Biomed

Seed

08/08/2024

N/A

$8m

Cellyrix

Seed

01/12/2024

N/A

$1.15m

DenovAI Biotech

DenovAI is a developer of gen artificial intelligence (AI)-physics platform for the de-novo design of therapeutic proteins, including antibodies and mini-proteins. The company's platform designs antibodies from scratch and then suggests which candidates will likely make effective drugs, enabling medical professionals to transform human health into new standards, accelerating drug discovery timelines, and addressing unmet medical needs with accurately designed molecules.

Dig. Health

Seed

28/02/2023

$2m

Promise Bio

Dig. Health

Seed

01/01/2024

N/A

$8.3m

Via AION Lab's venture seeding track from AstraZeneca and Pfizer.

ProPhet

Biomed

Seed

01/07/2024

N/A

Renasis Bio

Biomed

Seed

01/05/2025

N/A

TenAces

Biomed

Seed

01/02/2024

N/A

Exits (1)

Company Name		Exit Type	Date Announced	Amount	Remarks
abC Defghij		Acquired	12/01/2026	abCDe

Historic Portfolio (1)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Omec.ai

Ceased to Operate

Dig. Health

Seed

01/01/2022

$2m

Last Updated:	abCDe
IVC Number:	abCDe